CRISPR And CRISPR Associated Cas Genes Sales

CRISPR And CRISPR Associated Cas Genes Sales Market Outlook

The global CRISPR and CRISPR Associated Cas Genes market is projected to reach approximately USD 10.5 billion by 2035, exhibiting a compound annual growth rate (CAGR) of around 18.5% from 2025 to 2035. This robust growth can be attributed to the rapid advancements in gene-editing technologies and an increasing number of research activities aimed at exploring the potential of CRISPR in treating genetic disorders, enhancing crop yield, and furthering industrial applications. Additionally, the rising prevalence of genetic disorders and cancer has intensified the focus on developing more effective therapeutic options. Furthermore, the growing investments in biotechnology and pharmaceuticals by both private and public sectors are expected to bolster market growth as they drive innovation and research in gene editing. All these factors combined are creating a fertile ground for expanding the CRISPR market across various applications and regions.

Growth Factor of the Market

The CRISPR market is significantly driven by the increasing investments in research and development across various sectors including healthcare, agriculture, and industrial biotechnology. As scientists discover new applications for CRISPR technology, the demand for CRISPR products is expected to surge. Moreover, the rising prevalence of genetic diseases necessitates the development of effective gene therapies, thereby boosting the demand for CRISPR associated tools such as nuclease kits and design tools. Additionally, the successful completion of clinical trials and the introduction of CRISPR-based therapies into the market are further enhancing investor confidence, leading to increased funding and resource allocation for CRISPR-related projects. This financial influx not only accelerates research activities but also promotes collaboration between academic institutions, biotech firms, and pharmaceutical companies, propelling the market forward. The regulatory landscape is also becoming more favorable as governments and regulatory bodies begin to establish clearer guidelines for gene-editing technologies, thus facilitating their commercialization. Consequently, the convergence of these growth factors is expected to create a robust trajectory for the CRISPR market.

Key Highlights of the Market

• Rapid advancements in CRISPR technology enhancing its applications in various fields.
• Increasing awareness and investment in genetic research and therapies.
• Growing prevalence of genetic disorders stimulating demand for innovative treatments.
• Collaborative efforts between academia and industry boosting research initiatives.
• Favorable regulatory landscape encouraging the commercialization of CRISPR products.

By Product Type

CRISPR Plasmids:

CRISPR plasmids are essential tools for gene editing that enable the delivery of CRISPR components into target cells. They contain the necessary DNA sequences that encode for the Cas9 protein and the guide RNA (gRNA), which collectively facilitate the targeted editing of genes. The market for CRISPR plasmids is expanding rapidly as researchers increasingly prefer these systems for their simplicity and effectiveness. The versatile applications of CRISPR plasmids in various fields of research, including genetic engineering, functional genomics, and synthetic biology, contribute significantly to their demand. Additionally, the continuous development of more efficient and customizable plasmids is attracting a larger pool of researchers and institutions, further driving market growth. Moreover, the availability of user-friendly plasmid design tools enhances accessibility, making it easier for researchers to incorporate CRISPR techniques into their projects.

Nuclease Kits:

Nuclease kits are pivotal in the CRISPR market as they contain the necessary components for precise gene editing. These kits typically include the Cas nuclease, gRNA, and other essential reagents required for the CRISPR-Cas system to function effectively. The growing demand for targeted genome editing across various applications, such as gene therapy and agricultural biotechnology, is significantly boosting the market for nuclease kits. The ease of use and reproducibility of results provided by these kits make them attractive for both academic and commercial research laboratories. Furthermore, the advancements in nuclease technology, such as the development of Cas variants with enhanced specificity and reduced off-target effects, are propelling the adoption of these kits. As researchers continue to explore the potential of CRISPR technology, the demand for high-quality nuclease kits is anticipated to witness substantial growth.

Libraries/Tools:

Libraries and tools designed for CRISPR applications are crucial for conducting high-throughput screenings and functional genomics studies. These libraries often consist of collections of gRNAs that target various genes in the genome, allowing researchers to efficiently identify genetic functions and interactions. The expanding scope of CRISPR applications in biomedical research, agriculture, and industrial processes is leading to a surge in demand for these libraries. Researchers value the convenience and comprehensiveness of such tools, which facilitate large-scale experiments without the need for extensive custom design. The ongoing developments in library design and synthesis technology are enhancing the efficacy and specificity of CRISPR libraries, thus driving their adoption across various research sectors. As these tools become widely recognized for their contributions to groundbreaking discoveries, the market for CRISPR libraries and tools is set to grow significantly.

Design Tools:

Design tools play an instrumental role in the CRISPR market by providing researchers with the necessary platforms to create and optimize gRNAs tailored for specific gene targets. The enhancement of user-friendly software solutions and online platforms has made it increasingly accessible for researchers to design efficient CRISPR experiments. These tools typically incorporate algorithms that predict gRNA efficacy and potential off-target effects, ensuring that researchers can select the best candidates for their studies. The growing awareness of the importance of proper gRNA design to achieve successful gene editing outcomes is driving the demand for such tools. Moreover, as more laboratories adopt CRISPR technology, the need for robust design tools becomes paramount, fueling market expansion. The integration of artificial intelligence and machine learning into these design tools further enhances their precision and usability, paving the way for innovative applications in gene editing.

Other Products:

In addition to the primary product categories, the "Other Products" segment includes a variety of ancillary tools and reagents integral to the CRISPR workflow. This encompasses delivery systems, such as viral vectors and electroporation devices, as well as consumables like cell culture media and reagents required for downstream applications. The growth of this segment is closely linked to the rising demand for comprehensive CRISPR solutions that can facilitate the entire gene editing process. Researchers are increasingly seeking all-in-one kits that encompass everything from gRNA design to delivery and validation, thus driving the sales of ancillary products. Furthermore, the continuous innovation and introduction of new products tailored for specific applications are expected to enhance the offerings in this segment, contributing to its growth in the coming years.

By Application

Biomedical:

The biomedical application of CRISPR technology is one of the most compelling drivers of market growth. This sector is heavily focused on utilizing CRISPR for gene therapies aimed at treating genetic disorders, cancers, and infectious diseases. The ability of CRISPR to edit genes with precision and relative ease makes it an invaluable tool for researchers and clinicians investigating potential cures and therapeutic modalities. A wide range of clinical trials is currently underway, exploring the use of CRISPR in human subjects, which is expected to validate its efficacy and safety further. The increasing prevalence of genetic diseases is prompting pharmaceutical companies to invest heavily in CRISPR-based therapies, thereby significantly boosting the market. As success stories emerge from clinical investigations, the trust and reliance on CRISPR for biomedical applications are expected to expand markedly.

Agricultural:

In the agricultural sector, CRISPR technology is revolutionizing the way crops are engineered for improved yield, disease resistance, and environmental adaptability. This application leverages the precision of CRISPR to create genetically modified organisms (GMOs) that can withstand harsh environmental conditions and pests, thereby ensuring food security. With the growing global population and shrinking arable land, the need for sustainable agricultural solutions is more pressing than ever. Farmers and agribusinesses are increasingly turning to CRISPR as a viable alternative to traditional breeding methods due to its efficiency and speed. The ongoing research and development in CRISPR technology to enhance crop traits are expected to further propel its adoption in the agricultural sector, thereby contributing significantly to the overall market growth.

Industrial:

The industrial application of CRISPR is gaining traction as businesses recognize the potential of gene editing in enhancing product development and manufacturing processes. This includes utilizing CRISPR to engineer microorganisms for bioproduction, thus optimizing the yield of biofuels, pharmaceuticals, and other biochemicals. The biotechnology industry is increasingly integrating CRISPR technology into its operations to streamline processes and reduce costs. Furthermore, CRISPR-enabled innovations are also being explored in waste management and bioremediation, providing sustainable solutions to industrial challenges. As industries seek to improve their operational efficiency and address environmental issues, the adoption of CRISPR technology is likely to expand, contributing to a robust growth trajectory for the industrial segment.

Research:

CRISPR technology is an indispensable tool in modern scientific research, enabling researchers to explore gene functions, gene interactions, and the underlying mechanisms of diseases. This application has transformed the landscape of molecular biology, allowing for unprecedented insights into genetic systems. The ability to conduct genome-wide screenings and functional studies with high precision has made CRISPR a favored method among academic and research institutions. Furthermore, the rising funding for biomedical research and the increasing number of collaborative projects are fostering an environment ripe for CRISPR-based studies. As researchers continue to unravel the complexities of genetics with the aid of CRISPR, the demand for CRISPR products and services in the research sector is anticipated to continue its upward trend.

Others:

Aside from the primary applications mentioned, various other sectors are beginning to recognize the advantages of CRISPR technology. This includes applications in environmental science for biodiversity conservation and ecological genomics, where CRISPR can be utilized to study and manipulate the genomes of endangered species or invasive organisms. Additionally, CRISPR technology is being explored in synthetic biology for the design of custom organisms with novel functions. The flexibility and adaptability of CRISPR make it suitable for a wide range of applications, thereby driving market growth across diverse industries. As awareness of CRISPR's potential expands, more sectors are likely to harness its capabilities, further enriching the overall market landscape.

By User

Biopharmaceutical Companies:

Biopharmaceutical companies are among the primary users of CRISPR technology, leveraging its capabilities to develop innovative therapies and treatments. These companies are focused on harnessing CRISPR for precision medicine, targeted gene therapies, and the creation of genetically modified cell lines for drug development. The increasing prevalence of chronic diseases and genetic disorders is pushing biopharmaceutical companies to explore advanced therapeutic options, leading to investments in CRISPR-based research. Moreover, the collaboration between biopharmaceutical firms and research institutions to expedite the translation of CRISPR discoveries into clinical applications is further driving the market. As regulatory approvals for CRISPR-based therapies are obtained, biopharmaceutical companies are likely to expand their offerings, significantly impacting market growth.

Academic & Research Institutes:

Academic and research institutions are pivotal in advancing CRISPR technology through fundamental research and exploration of novel applications. These entities are often at the forefront of scientific discoveries, utilizing CRISPR tools to conduct extensive studies on gene functions and interactions. The growing emphasis on genetic research, coupled with increasing funding for scientific initiatives, is promoting the adoption of CRISPR among academic institutions. Furthermore, the collaborative nature of research projects encourages the sharing of methodologies and findings, leading to rapid advancements in the field. As more researchers recognize the power of CRISPR for groundbreaking studies, the demand for related products and services is expected to rise steeply, thereby enhancing the market dynamics.

Contract Research Organizations:

Contract Research Organizations (CROs) play a crucial role in supporting biopharmaceutical companies and academic institutions by providing specialized services related to CRISPR technology. These organizations offer expertise in designing and conducting studies that require gene editing, including preclinical trials and product development. The growing reliance on CROs to conduct complex experiments and research is a significant driver for the CRISPR market. Additionally, the increasing trend of outsourcing research and development activities allows companies and institutions to focus on their core competencies while leveraging the specialized skills of CROs. As the demand for CRISPR applications expands, the services provided by CROs will be instrumental in facilitating research efforts and accelerating the commercialization of CRISPR technologies.

Others:

Beyond the primary user categories, there is a growing number of industries and sectors beginning to adopt CRISPR technology for various applications. This includes agricultural companies that utilize CRISPR for developing genetically modified crops, environmental organizations exploring its potential for conservation efforts, and manufacturing industries optimizing production processes. The increasing awareness of CRISPR's versatility and effectiveness is encouraging diverse users to incorporate these tools into their operations. Moreover, as educational institutions recognize the importance of teaching gene editing techniques, the demand for CRISPR products and resources is expected to rise across various educational programs. This broader adoption across different user groups is likely to enrich the market landscape and contribute to its sustained growth.

By Region

The North American region holds a significant share of the CRISPR and CRISPR Associated Cas Genes market, reflecting the presence of leading biopharmaceutical companies, robust research institutions, and strong government support for biotechnology initiatives. With a market size of approximately USD 4.5 billion in 2025, North America is projected to maintain a CAGR of about 19% during the forecast period. The U.S., in particular, is at the forefront of CRISPR research and application, driven by substantial funding from government agencies, and is home to numerous biotechnology firms dedicated to advancing gene editing solutions. The increasing prevalence of genetic disorders and chronic diseases in this region is further propelling the demand for innovative CRISPR-based therapies and applications.

Europe is also witnessing substantial growth in the CRISPR market, driven by a well-established biotechnology sector and increasing investments in research and development activities. With a market size estimated at around USD 3.2 billion in 2025, Europe is expected to grow at a CAGR of 17.2% during the forecast period. The region boasts a strong network of academic institutions and research organizations dedicated to exploring CRISPR technologies, contributing to numerous collaborative projects and advancements in gene editing. Additionally, the European Union's supportive regulatory framework for genetic research and biotechnological innovations is encouraging the development and commercialization of CRISPR products, thereby enhancing market growth. As more breakthroughs emerge from European research initiatives, the adoption of CRISPR technology across various applications is anticipated to increase significantly.

Opportunities

The CRISPR and CRISPR Associated Cas Genes market presents a plethora of opportunities driven by the rapid pace of technological advancements and the growing demand for innovative solutions in healthcare, agriculture, and various industrial applications. One notable opportunity is the increasing emphasis on precision medicine, where CRISPR can play a crucial role in developing targeted therapies for genetic disorders and cancer. As the medical community continues to explore personalized treatment options, CRISPR technology could facilitate the creation of tailored therapies that address the specific genetic makeup of patients. This potential to revolutionize patient care is attracting investments from biopharmaceutical companies eager to capitalize on the benefits of CRISPR in therapeutic interventions. Additionally, the agricultural sector is witnessing significant interest in utilizing CRISPR for crop improvement, which presents a vast opportunity for businesses engaged in agricultural biotechnology to develop and commercialize genetically modified crops that meet the demands of a growing population.

Another area of opportunity lies in the expansion of CRISPR applications in industrial biotechnology. As industries increasingly seek sustainable and efficient solutions for production processes, CRISPR technology can be employed to engineer microbial strains optimized for bioproduction. This can lead to enhanced yields of biofuels, pharmaceuticals, and other biochemicals, ultimately reducing costs and environmental impact. Furthermore, there is an increasing recognition of the role CRISPR can play in addressing pressing global challenges such as climate change and food security. As stakeholders across various sectors acknowledge the transformative potential of CRISPR technology, an ecosystem for collaboration and innovation is likely to emerge, creating avenues for new partnerships and ventures in research and commercialization.

Threats

While the CRISPR market holds immense potential, it also faces several threats that could impede its growth trajectory. One of the primary concerns is the ethical implications associated with gene editing, especially in human applications. The ability to modify genes raises critical moral questions regarding the potential for unintended consequences and the long-term impact on the genetic pool of populations. As discussions around "designer babies" and genetic modifications gain traction, public opinion could significantly influence regulatory policies, potentially leading to stricter regulations that may stifle innovation and application. Additionally, the growing competition within the biotechnology sector could lead to market saturation, limiting the profitability of CRISPR-based products. Companies must continually innovate and differentiate their offerings to remain competitive, which can be a daunting challenge in a rapidly evolving market landscape.

The potential for off-target effects and unintended modifications during the gene editing process also poses a significant concern for the CRISPR market. Although advancements have been made to enhance the specificity of CRISPR systems, the risk of unintended genetic alterations remains a reality that researchers must navigate. Such occurrences could undermine the credibility of CRISPR technology and deter potential users from adopting it. Furthermore, regulatory hurdles and the need for comprehensive safety evaluations could prolong the commercialization process, delaying the introduction of CRISPR-based solutions to the market. These combined threats necessitate ongoing research, robust regulatory frameworks, and transparent communication with stakeholders to mitigate risks and ensure responsible use of CRISPR technology.

Competitor Outlook

• Editas Medicine
• CRISPR Therapeutics
• Intellia Therapeutics
• Caribou Biosciences
• Regeneron Pharmaceuticals
• Amgen
• Agilent Technologies
• Thermo Fisher Scientific
• Integrated DNA Technologies
• Sigma-Aldrich (MilliporeSigma)
• New England Biolabs
• Takara Bio
• Lonza Group
• Bristol-Myers Squibb
• DuPont

The competitive landscape of the CRISPR and CRISPR Associated Cas Genes market is characterized by the presence of numerous established players, emerging startups, and academic institutions engaged in pioneering research. Major companies such as Editas Medicine and CRISPR Therapeutics are at the forefront of developing CRISPR-based therapies targeting genetic disorders and cancers, leveraging their proprietary technologies to differentiate themselves in a crowded market. These firms are investing heavily in research and development to innovate and advance their product offerings, aiming to capture a significant share of the expanding market. Collaboration between industry leaders and research institutions is also prevalent, as joint ventures enable the pooling of resources and expertise to drive CRISPR applications forward.

Apart from biotechnology firms, established players in the life sciences sector, such as Thermo Fisher Scientific and Agilent Technologies, are expanding their portfolios to include CRISPR products and tools. These companies leverage their extensive distribution networks and existing customer bases to penetrate the CRISPR market effectively. Additionally, strategic partnerships and acquisitions among companies are expected to shape the competitive landscape as firms seek to enhance their technological capabilities and market reach. As the awareness and adoption of CRISPR technology continue to grow, competition is anticipated to intensify, leading to further innovation and advancements in the field.

Key players like Intellia Therapeutics and Caribou Biosciences are focusing on developing next-generation CRISPR technologies that promise improved efficacy and safety profiles. These companies are exploring novel delivery methods and alternative CRISPR systems to enhance the precision and reduce off-target effects associated with traditional CRISPR approaches. As research progresses, the emergence of new startups specializing in CRISPR tools and applications is also expected, fostering a culture of innovation and driving the market forward. As such, the competitive dynamics of the CRISPR market are poised for continuous evolution, with the potential for disruptive technologies and collaborative initiatives shaping its future.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 DuPont
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Takara Bio
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Lonza Group
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Editas Medicine
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 CRISPR Therapeutics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Caribou Biosciences
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 New England Biolabs
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Agilent Technologies
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bristol-Myers Squibb
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Intellia Therapeutics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Integrated DNA Technologies
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Sigma-Aldrich (MilliporeSigma)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 CRISPR And CRISPR Associated Cas Genes Sales Market, By User
    • 6.1.1 Biopharmaceutical Companies
    • 6.1.2 Academic & Research Institutes
    • 6.1.3 Contract Research Organizations
    • 6.1.4 Others
  • 6.2 CRISPR And CRISPR Associated Cas Genes Sales Market, By Application
    • 6.2.1 Biomedical
    • 6.2.2 Agricultural
    • 6.2.3 Industrial
    • 6.2.4 Research
    • 6.2.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 CRISPR And CRISPR Associated Cas Genes Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global CRISPR And CRISPR Associated Cas Genes Sales market is categorized based on

By Application

• Biomedical
• Agricultural
• Industrial
• Research
• Others

By User

• Biopharmaceutical Companies
• Academic & Research Institutes
• Contract Research Organizations
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Editas Medicine
• CRISPR Therapeutics
• Intellia Therapeutics
• Caribou Biosciences
• Regeneron Pharmaceuticals
• Amgen
• Agilent Technologies
• Thermo Fisher Scientific
• Integrated DNA Technologies
• Sigma-Aldrich (MilliporeSigma)
• New England Biolabs
• Takara Bio
• Lonza Group
• Bristol-Myers Squibb
• DuPont